GlycoMar's business model uses R&D investment to generate valuable intellectual property based on our unique expertise in glycobiology.
In the near term development of cosmuer healthcare and personal care products are generating value, and in the longer term significant value will be generated for investors through the out-licensing of anti-inflammatory drugs that have completed early phase clinical trails.
The Company's core business is the development of intellectual property to address unmet helathcare need. GlycoMar achieves this through the discovery of new compounds based on glycobiology. We combine the capabilities necessary for the discovery of novel product candidates and their development for the pharmaceutical and personal care markets.
We are exploiting these capabilities to the maximum; generating short-medium term income through collaboration fees and nutraceutical & cosmeceutical development, and long term value through drug development.